Skip to content

SonoThera

3 viewers · 30d

Total raised

$125.5M

+$125.5M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $125.5M
ROUNDS
1
INVESTORS
22
FOUNDED
2021
HQ
South San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

SonoThera develops nonviral genetic medicines delivered with focused clinical ultrasound. Its RIPPLE platform pairs proprietary acoustic profiles with circulating gas-filled microbubbles to transiently open cell membranes and deliver genetic payloads into targeted organs without a viral vector. Lead preclinical programs target Duchenne muscular dystrophy, autosomal dominant polycystic kidney disease, X-linked Alport syndrome, hemophilia A, and cardiac indications, with first clinical trials planned for 2027. The company raised a $60.75M Series A and closed an oversubscribed $125M Series B.

What sets it apart

Because delivery is physical rather than viral, the platform is redosable, carries payloads of effectively unlimited size (DNA, RNA, gene editors, siRNA, ASOs), and avoids the immunogenicity and dosing ceilings that constrain AAV and lipid-nanoparticle approaches, while targeting nearly any organ using standard clinical ultrasound equipment.

Funding history

1 round
EquityJun 8, 2026
Form D
+$125.5M$125.5M total

Latest SEC filings

via EDGAR · CIK 0001945154
Form D · Jun 8, 2026NewView on EDGAR

Products

1 tracked

RIPPLE

Genetic medicine delivery platform

An ultrasound-mediated delivery (UMD) platform that combines proprietary acoustic profiles with microbubbles to transiently open pathways into cells in a targeted organ, allowing genetic payloads to enter without a viral vector.

  • Nonviral, ultrasound-guided delivery using standard clinical ultrasound
  • Broad but highly targeted biodistribution with limited off-target exposure
  • Payloads of unlimited size: DNA, RNA, gene editors, siRNAs, ASOs
  • Redosable with stable therapeutic expression over time

Links

WebsiteLinkedInSEC EDGAR filings